Showing results (241-250 of 271) with videos related to

Sort By:
Pageof 28
Plos One|January 21, 2026
Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromasHua Li, Alexander Pemov, Robert Allaway, et al.
Plos One|March 10, 2026
Correction: Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromasHua Li, Alexander Pemov, Robert Allaway, et al.
Neurosurgery|February 27, 2026
Clinical Outcomes Following Surgical Resection for Patients With Malignant Peripheral Nerve Sheath TumorsMelanie Alfonzo Horowitz, Jawad M Khalifeh, Xinlan Yang, et al.
Neuro-Oncology Practice|July 15, 2024
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseasesBritt A E Dhaenens, Günter Heimann, Annette Bakker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Neuro-Oncology|March 12, 2026
Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain TumorsStuart A Grossman, Amy Barone, Roy E Strowd, et al.
Acta Neuropathologica|October 7, 2020
Epigenomic, genomic, and transcriptomic landscape of schwannomatosisSheila Mansouri, Suganth Suppiah, Yasin Mamatjan, et al.
Neuro-Oncology|April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidityAndrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Molecular Cancer Therapeutics|July 5, 2021
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or MeningiomaMatthias A Karajannis, Audrey Mauguen, Ekrem Maloku, et al.
American Journal of Medical Genetics. Part A|December 6, 2011
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2Jaishri O Blakeley, D Gareth Evans, John Adler, et al.
Pageof 28